Cargando…
Targeting Inflammatory Cytokines to Improve Type 2 Diabetes Control
Type 2 diabetes (T2D) is one of the most common chronic metabolic disorders in adulthood worldwide, whose pathophysiology includes an abnormal immune response accompanied by cytokine dysregulation and inflammation. As the T2D-related inflammation and its progression were associated with the balance...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8455209/ https://www.ncbi.nlm.nih.gov/pubmed/34557550 http://dx.doi.org/10.1155/2021/7297419 |
_version_ | 1784570626128740352 |
---|---|
author | Velikova, Tsvetelina V. Kabakchieva, Plamena P. Assyov, Yavor S. Georgiev, Tsvetoslav А. |
author_facet | Velikova, Tsvetelina V. Kabakchieva, Plamena P. Assyov, Yavor S. Georgiev, Tsvetoslav А. |
author_sort | Velikova, Tsvetelina V. |
collection | PubMed |
description | Type 2 diabetes (T2D) is one of the most common chronic metabolic disorders in adulthood worldwide, whose pathophysiology includes an abnormal immune response accompanied by cytokine dysregulation and inflammation. As the T2D-related inflammation and its progression were associated with the balance between pro and anti-inflammatory cytokines, anticytokine treatments might represent an additional therapeutic option for T2D patients. This review focuses on existing evidence for antihyperglycemic properties of disease-modifying antirheumatic drugs (DMARDs) and anticytokine agents (anti-TNF-α, anti-interleukin-(IL-) 6, -IL-1, -IL-17, -IL-23, etc.). Emphasis is placed on their molecular mechanisms and on the biological rationale for clinical use. Finally, we briefly summarize the results from experimental model studies and promising clinical trials about the potential of anticytokine therapies in T2D, discussing the effects of these drugs on systemic and islet inflammation, beta-cell function, insulin secretion, and insulin sensitivity. |
format | Online Article Text |
id | pubmed-8455209 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Hindawi |
record_format | MEDLINE/PubMed |
spelling | pubmed-84552092021-09-22 Targeting Inflammatory Cytokines to Improve Type 2 Diabetes Control Velikova, Tsvetelina V. Kabakchieva, Plamena P. Assyov, Yavor S. Georgiev, Tsvetoslav А. Biomed Res Int Review Article Type 2 diabetes (T2D) is one of the most common chronic metabolic disorders in adulthood worldwide, whose pathophysiology includes an abnormal immune response accompanied by cytokine dysregulation and inflammation. As the T2D-related inflammation and its progression were associated with the balance between pro and anti-inflammatory cytokines, anticytokine treatments might represent an additional therapeutic option for T2D patients. This review focuses on existing evidence for antihyperglycemic properties of disease-modifying antirheumatic drugs (DMARDs) and anticytokine agents (anti-TNF-α, anti-interleukin-(IL-) 6, -IL-1, -IL-17, -IL-23, etc.). Emphasis is placed on their molecular mechanisms and on the biological rationale for clinical use. Finally, we briefly summarize the results from experimental model studies and promising clinical trials about the potential of anticytokine therapies in T2D, discussing the effects of these drugs on systemic and islet inflammation, beta-cell function, insulin secretion, and insulin sensitivity. Hindawi 2021-09-13 /pmc/articles/PMC8455209/ /pubmed/34557550 http://dx.doi.org/10.1155/2021/7297419 Text en Copyright © 2021 Tsvetelina V. Velikova et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Article Velikova, Tsvetelina V. Kabakchieva, Plamena P. Assyov, Yavor S. Georgiev, Tsvetoslav А. Targeting Inflammatory Cytokines to Improve Type 2 Diabetes Control |
title | Targeting Inflammatory Cytokines to Improve Type 2 Diabetes Control |
title_full | Targeting Inflammatory Cytokines to Improve Type 2 Diabetes Control |
title_fullStr | Targeting Inflammatory Cytokines to Improve Type 2 Diabetes Control |
title_full_unstemmed | Targeting Inflammatory Cytokines to Improve Type 2 Diabetes Control |
title_short | Targeting Inflammatory Cytokines to Improve Type 2 Diabetes Control |
title_sort | targeting inflammatory cytokines to improve type 2 diabetes control |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8455209/ https://www.ncbi.nlm.nih.gov/pubmed/34557550 http://dx.doi.org/10.1155/2021/7297419 |
work_keys_str_mv | AT velikovatsvetelinav targetinginflammatorycytokinestoimprovetype2diabetescontrol AT kabakchievaplamenap targetinginflammatorycytokinestoimprovetype2diabetescontrol AT assyovyavors targetinginflammatorycytokinestoimprovetype2diabetescontrol AT georgievtsvetoslava targetinginflammatorycytokinestoimprovetype2diabetescontrol |